Jun. 11 at 9:45 AM
Dear God, all I need is
$50K to buy more..... Ya seee the market is completely blind to the absolute goldmine
$SLS is sitting on.
Standard oncology multiples on SLS-009 alone (
$600M-
$700M annual revenue) justify
$15-
$28/share. Add a successful Phase 3 REGAL unblinding for GPS (
$1B-
$1.2B peak annual AML revenue), and a GSK-style buyout (from this week) translates to
$46-
$53+/share on our current float.
But here is the real kicker: GPS targets WT1—the #1 oncology target with 20+ other cancer indications in the pipeline (ovarian, CRC, multiple myeloma).
If AML alone commands a
$10.6B valuation, multiplying that across a platform targeting 20+ other multi-billion dollar markets puts the true long-term value at a staggering
$215+ per share—translating to a massive
$42.2 Billion total buyout valuation. Let that take you thru this month....we're almost to the finish line!
$PFE $ABBV $PFE $MRK